Comparative Pharmacology
Head-to-head clinical analysis: MEPIVACAINE HYDROCHLORIDE versus TETRACAINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEPIVACAINE HYDROCHLORIDE versus TETRACAINE HYDROCHLORIDE.
MEPIVACAINE HYDROCHLORIDE vs TETRACAINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mepivacaine hydrochloride is an amide-type local anesthetic that reversibly blocks nerve impulse propagation by binding to sodium channels in the neuronal cell membrane, thereby stabilizing the membrane and preventing depolarization.
Tetracaine hydrochloride is a local anesthetic of the ester type that reversibly blocks nerve conduction by decreasing sodium ion permeability across the neuronal membrane, thereby stabilizing the membrane and preventing the initiation and transmission of nerve impulses.
1-2% solution, 5-20 mL local infiltration or nerve block, maximum 400 mg per procedure.
Topical: 0.5-2% solution or ointment applied to affected area up to 4 times daily as needed. Maximum single dose: 20 mL of 2% solution (400 mg). Spinal anesthesia: 0.5% solution, 2-3 mL (10-15 mg) injected intrathecally.
None Documented
None Documented
Terminal elimination half-life approximately 2 hours (range 1.5–3 hours). In neonates and patients with hepatic dysfunction, half-life may be prolonged up to 8–10 hours.
Terminal elimination half-life is approximately 1.5–3 minutes in plasma due to rapid hydrolysis; clinical effect duration is dose-dependent (15–30 minutes for topical anesthesia).
Primarily hepatic metabolism via amidase enzymes; ~95% excreted as metabolites in bile and feces, <5% unchanged in urine.
Primarily metabolized by plasma pseudocholinesterase; renal excretion of metabolites accounts for >95% of elimination, with <2% excreted unchanged in urine. Biliary/fecal elimination is negligible.
Category C
Category C
Local Anesthetic
Local Anesthetic